首页 > 最新文献

Clinical Medicine Insights-Endocrinology and Diabetes最新文献

英文 中文
Prenatal Androgen Excess Induces Multigenerational Effects on Female and Male Descendants. 产前雄激素过多对女性和男性后代产生多代影响
IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-11 eCollection Date: 2023-01-01 DOI: 10.1177/11795514231196461
Giselle Adriana Abruzzese, Silvana Rocio Ferreira, Maria José Ferrer, Aimé Florencia Silva, Alicia Beatriz Motta

Background: It is still unelucidated how hormonal alterations affect developing organisms and their descendants. Particularly, the effects of androgen levels are of clinical relevance as they are usually high in women with Polycystic Ovary Syndrome (PCOS). Moreover, it is still unknown how androgens may affect males' health and their descendants.

Objectives: We aimed to evaluate the multigenerational effect of prenatal androgen excess until a second generation at early developmental stages considering both maternal and paternal effects.

Design and methods: This is an animal model study. Female rats (F0) were exposed to androgens during pregnancy by injections of 1 mg of testosterone to obtain prenatally hyperandrogenized (PH) animals (F1), leading to a well-known animal model that resembles PCOS features. A control (C) group was obtained by vehicle injections. The PH-F1 animals were crossed with C males (m) or females (f) and C animals were also mated, thus obtaining 3 different mating groups: Cf × Cm, PHf × Cm, Cf × PHm and their offspring (F2).

Results: F1-PHf presented altered glucose metabolism and lipid profile compared to F1-C females. In addition, F1-PHf showed an increased time to mating with control males compared to the C group. At gestational day 14, we found alterations in glucose and total cholesterol serum levels and in the placental size of the pregnant F1-PHf and Cf mated to F1-PHm. The F2 offspring resulting from F1-PH mothers or fathers showed alterations in their growth, size, and glucose metabolism up to early post-natal development in a sex-dependent manner, being the females born to F1-PHf the most affected ones.

Conclusion: androgen exposure during intrauterine life leads to programing effects in females and males that affect offspring health in a sex-dependent manner, at least up-to a second generation. In addition, this study suggests paternally mediated effects on the F2 offspring development.

背景:荷尔蒙的变化如何影响发育中的生物体及其后代,目前尚无定论。尤其是雄激素水平的影响与临床相关,因为患有多囊卵巢综合症(PCOS)的女性体内雄激素水平通常较高。此外,雄激素对男性健康及其后代的影响尚不清楚:我们旨在评估产前雄激素过多对第二代早期发育阶段的多代影响,同时考虑母系和父系的影响:这是一项动物模型研究。雌性大鼠(F0)在怀孕期间通过注射 1 毫克睾酮暴露于雄激素,从而获得产前雄激素过高(PH)动物(F1),这就是著名的类似多囊卵巢综合征特征的动物模型。对照组(C)通过注射药物获得。PH-F1 动物与 C 组雄性(m)或雌性(f)杂交,C 组动物也进行交配,从而得到 3 个不同的交配组:结果:结果:与F1-C雌鼠相比,F1-PHf的糖代谢和血脂谱发生了改变。此外,与 C 组相比,F1-PHf 与对照雄性交配的时间延长。在妊娠第 14 天,我们发现与 F1-PHm 交配的 F1-PHf 和 Cf 孕妇的血糖和总胆固醇血清水平以及胎盘大小发生了变化。结论:宫内雄激素暴露会导致雌性和雄性产生程序效应,以性别依赖的方式影响后代的健康,至少影响到第二代。此外,这项研究还表明,父系介导的效应会影响子二代的发育。
{"title":"Prenatal Androgen Excess Induces Multigenerational Effects on Female and Male Descendants.","authors":"Giselle Adriana Abruzzese, Silvana Rocio Ferreira, Maria José Ferrer, Aimé Florencia Silva, Alicia Beatriz Motta","doi":"10.1177/11795514231196461","DOIUrl":"10.1177/11795514231196461","url":null,"abstract":"<p><strong>Background: </strong>It is still unelucidated how hormonal alterations affect developing organisms and their descendants. Particularly, the effects of androgen levels are of clinical relevance as they are usually high in women with Polycystic Ovary Syndrome (PCOS). Moreover, it is still unknown how androgens may affect males' health and their descendants.</p><p><strong>Objectives: </strong>We aimed to evaluate the multigenerational effect of prenatal androgen excess until a second generation at early developmental stages considering both maternal and paternal effects.</p><p><strong>Design and methods: </strong>This is an animal model study. Female rats (F0) were exposed to androgens during pregnancy by injections of 1 mg of testosterone to obtain prenatally hyperandrogenized (PH) animals (F1), leading to a well-known animal model that resembles PCOS features. A control (C) group was obtained by vehicle injections. The PH-F1 animals were crossed with C males (m) or females (f) and C animals were also mated, thus obtaining 3 different mating groups: Cf × Cm, PHf × Cm, Cf × PHm and their offspring (F2).</p><p><strong>Results: </strong>F1-PHf presented altered glucose metabolism and lipid profile compared to F1-C females. In addition, F1-PHf showed an increased time to mating with control males compared to the C group. At gestational day 14, we found alterations in glucose and total cholesterol serum levels and in the placental size of the pregnant F1-PHf and Cf mated to F1-PHm. The F2 offspring resulting from F1-PH mothers or fathers showed alterations in their growth, size, and glucose metabolism up to early post-natal development in a sex-dependent manner, being the females born to F1-PHf the most affected ones.</p><p><strong>Conclusion: </strong>androgen exposure during intrauterine life leads to programing effects in females and males that affect offspring health in a sex-dependent manner, at least up-to a second generation. In addition, this study suggests paternally mediated effects on the F2 offspring development.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"16 ","pages":"11795514231196461"},"PeriodicalIF":2.7,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/ff/10.1177_11795514231196461.PMC10496475.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10260566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health Profiles of Marshallese With and Without a Type 2 Diabetes Diagnosis in the Republic of the Marshall Islands. 马绍尔群岛共和国患有和未患有 2 型糖尿病的马绍尔人的健康概况。
IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-08-23 eCollection Date: 2023-01-01 DOI: 10.1177/11795514231183595
Jennifer A Andersen, Holly C Felix, Joseph R Malhis, Erin Gloster, Pearl A McElfish

Background: The Republic of the Marshall Islands (RMI) faces a high prevalence of type 2 diabetes (T2DM).

Objectives: The aim of the study is to document the health of Marshallese with and without a T2DM diagnosis to inform future interventions.

Design: Data are from screenings collected in preparation for a diabetes education intervention. Data, including HbA1c, random glucose, cholesterol, weight, and self-rated health, were collected.

Methods: Kruskal-Wallis and Fisher's exact tests were used to identify differences in participants with and without T2DM diagnosis.

Results: There were significant differences in both HbA1c level (P ⩽ .0001) and glucose level (P ⩽ .0001) between the diagnosed T2DM and non-diagnosed T2DM groups, as well as diastolic blood pressure (P = .0179), systolic blood pressure (P = .0003), and pulse pressure (P = .0023). There were no differences in weight, body mass index (BMI), high density lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol, or self-rated health. Marshallese without a T2DM diagnosis have signs of insulin resistance, including elevated glucose and triglyceride levels.

Conclusion: The results indicate a need for a socioecological approach to T2DM interventions, and interventions in the RMI should consider inclusion of blood pressure and cholesterol management. There is a need for interventions to prevent prediabetes and its progression to T2DM.

背景:马绍尔群岛共和国面临着 2 型糖尿病(T2DM)的高发病率:马绍尔群岛共和国(RMI)面临着2型糖尿病(T2DM)的高发病率:研究目的:记录马绍尔群岛被诊断为2型糖尿病和未被诊断为2型糖尿病的人的健康状况,为今后的干预措施提供依据:数据来自为准备糖尿病教育干预而进行的筛查。收集的数据包括 HbA1c、随机血糖、胆固醇、体重和自我健康评价:方法:采用 Kruskal-Wallis 检验和费雪精确检验来确定有无 T2DM 诊断的参与者之间的差异:结果:确诊 T2DM 组和未确诊 T2DM 组的 HbA1c 水平(P ⩽ .0001)和血糖水平(P ⩽ .0001)以及舒张压(P = .0179)、收缩压(P = .0003 )和脉压(P = .0023)均有明显差异。体重、体重指数(BMI)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、总胆固醇和自评健康状况均无差异。未确诊 T2DM 的马绍尔人有胰岛素抵抗的迹象,包括葡萄糖和甘油三酯水平升高:结果表明,有必要采用社会生态学方法对 T2DM 进行干预,在马绍尔群岛的干预措施应考虑纳入血压和胆固醇管理。有必要采取干预措施,预防糖尿病前期及其向 T2DM 的发展。
{"title":"Health Profiles of Marshallese With and Without a Type 2 Diabetes Diagnosis in the Republic of the Marshall Islands.","authors":"Jennifer A Andersen, Holly C Felix, Joseph R Malhis, Erin Gloster, Pearl A McElfish","doi":"10.1177/11795514231183595","DOIUrl":"10.1177/11795514231183595","url":null,"abstract":"<p><strong>Background: </strong>The Republic of the Marshall Islands (RMI) faces a high prevalence of type 2 diabetes (T2DM).</p><p><strong>Objectives: </strong>The aim of the study is to document the health of Marshallese with and without a T2DM diagnosis to inform future interventions.</p><p><strong>Design: </strong>Data are from screenings collected in preparation for a diabetes education intervention. Data, including HbA1c, random glucose, cholesterol, weight, and self-rated health, were collected.</p><p><strong>Methods: </strong>Kruskal-Wallis and Fisher's exact tests were used to identify differences in participants with and without T2DM diagnosis.</p><p><strong>Results: </strong>There were significant differences in both HbA1c level (<i>P</i> ⩽ .0001) and glucose level (<i>P</i> ⩽ .0001) between the diagnosed T2DM and non-diagnosed T2DM groups, as well as diastolic blood pressure (<i>P</i> = .0179), systolic blood pressure (<i>P</i> = .0003), and pulse pressure (<i>P</i> = .0023). There were no differences in weight, body mass index (BMI), high density lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol, or self-rated health. Marshallese without a T2DM diagnosis have signs of insulin resistance, including elevated glucose and triglyceride levels.</p><p><strong>Conclusion: </strong>The results indicate a need for a socioecological approach to T2DM interventions, and interventions in the RMI should consider inclusion of blood pressure and cholesterol management. There is a need for interventions to prevent prediabetes and its progression to T2DM.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"16 ","pages":"11795514231183595"},"PeriodicalIF":2.7,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/3b/10.1177_11795514231183595.PMC10449571.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10356859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Graves' Disease in Children: An Update. 儿童巴塞杜氏病:最新进展。
IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-05-03 eCollection Date: 2023-01-01 DOI: 10.1177/11795514221150615
Kotb Abbass Metwalley, Hekma Saad Farghaly

Graves' disease (GD) is the most common cause of hyperthyroidism in children. A common GD symptom is a goiter. The usual biochemical profile in children with GD is a decreased thyroid hormone stimulating hormone (TSH) level and high free thyroxine (FT4) and free triiodothyronine (FT3) concentrations. The presence of thyroid receptor antibodies (TRAb) is the most important specific immunological sign for diagnosing GD. The treatment choices for pediatric GD are anti-thyroid drugs (ATDs), radioiodine, and thyroidectomy, but the risks and benefits of each modality are different. Management recommendations include the first-line use of a prolonged course of ATDs for at least 3 years and potentially 5 years or more. Rituximab and Teprotumumab are new novel alternative medications for the treatment of adult patients with GD and Graves' orbitopathy respectively, but evidence of the efficacy and safety of these drugs in pediatric patients with GD is lacking.

巴塞杜氏病(GD)是儿童甲状腺功能亢进症最常见的病因。常见的GD症状是甲状腺肿大。GD患儿通常的生化指标是促甲状腺激素(TSH)水平降低,游离甲状腺素(FT4)和游离三碘甲状腺原氨酸(FT3)浓度升高。甲状腺受体抗体(TRAb)的存在是诊断 GD 最重要的特异性免疫学标志。小儿 GD 的治疗方法有抗甲状腺药物(ATD)、放射性碘和甲状腺切除术,但每种方法的风险和益处各不相同。治疗建议包括一线使用长疗程的抗甲状腺药物,疗程至少3年,也可能5年或更长。利妥昔单抗(Rituximab)和特普鲁单抗(Teprotumumab)是分别用于治疗成人GD患者和巴塞杜氏眶病患者的新型替代药物,但这些药物在儿童GD患者中的疗效和安全性尚缺乏证据。
{"title":"Graves' Disease in Children: An Update.","authors":"Kotb Abbass Metwalley, Hekma Saad Farghaly","doi":"10.1177/11795514221150615","DOIUrl":"10.1177/11795514221150615","url":null,"abstract":"<p><p>Graves' disease (GD) is the most common cause of hyperthyroidism in children. A common GD symptom is a goiter. The usual biochemical profile in children with GD is a decreased thyroid hormone stimulating hormone (TSH) level and high free thyroxine (FT4) and free triiodothyronine (FT3) concentrations. The presence of thyroid receptor antibodies (TRAb) is the most important specific immunological sign for diagnosing GD. The treatment choices for pediatric GD are anti-thyroid drugs (ATDs), radioiodine, and thyroidectomy, but the risks and benefits of each modality are different. Management recommendations include the first-line use of a prolonged course of ATDs for at least 3 years and potentially 5 years or more. Rituximab and Teprotumumab are new novel alternative medications for the treatment of adult patients with GD and Graves' orbitopathy respectively, but evidence of the efficacy and safety of these drugs in pediatric patients with GD is lacking.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"16 ","pages":"11795514221150615"},"PeriodicalIF":2.7,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/09/10.1177_11795514221150615.PMC10161304.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9423024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bioinformatics Analysis of Next Generation Sequencing Data Identifies Molecular Biomarkers Associated With Type 2 Diabetes Mellitus. 下一代测序数据的生物信息学分析确定了与 2 型糖尿病相关的分子生物标记物。
IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-02-20 eCollection Date: 2023-01-01 DOI: 10.1177/11795514231155635
Varun Alur, Varshita Raju, Basavaraj Vastrad, Chanabasayya Vastrad, Satish Kavatagimath, Shivakumar Kotturshetti

Background: Type 2 diabetes mellitus (T2DM) is the most common metabolic disorder. The aim of the present investigation was to identify gene signature specific to T2DM.

Methods: The next generation sequencing (NGS) dataset GSE81608 was retrieved from the gene expression omnibus (GEO) database and analyzed to identify the differentially expressed genes (DEGs) between T2DM and normal controls. Then, Gene Ontology (GO) and pathway enrichment analysis, protein-protein interaction (PPI) network, modules, miRNA (micro RNA)-hub gene regulatory network construction and TF (transcription factor)-hub gene regulatory network construction, and topological analysis were performed. Receiver operating characteristic curve (ROC) analysis was also performed to verify the prognostic value of hub genes.

Results: A total of 927 DEGs (461 were up regulated and 466 down regulated genes) were identified in T2DM. GO and REACTOME results showed that DEGs mainly enriched in protein metabolic process, establishment of localization, metabolism of proteins, and metabolism. The top centrality hub genes APP, MYH9, TCTN2, USP7, SYNPO, GRB2, HSP90AB1, UBC, HSPA5, and SQSTM1 were screened out as the critical genes. ROC analysis provides prognostic value of hub genes.

Conclusion: The potential crucial genes, especially APP, MYH9, TCTN2, USP7, SYNPO, GRB2, HSP90AB1, UBC, HSPA5, and SQSTM1, might be linked with risk of T2DM. Our study provided novel insights of T2DM into genetics, molecular pathogenesis, and novel therapeutic targets.

背景:2 型糖尿病(T2DM)是最常见的代谢性疾病。本研究旨在确定 T2DM 的特异性基因特征:方法:从基因表达总括(GEO)数据库中检索并分析了新一代测序(NGS)数据集 GSE81608,以确定 T2DM 和正常对照之间的差异表达基因(DEGs)。然后进行了基因本体(GO)和通路富集分析、蛋白-蛋白相互作用(PPI)网络、模块、miRNA(微 RNA)-中枢基因调控网络构建、TF(转录因子)-中枢基因调控网络构建和拓扑分析。同时还进行了接收者操作特征曲线(ROC)分析,以验证枢纽基因的预后价值:结果:在 T2DM 中总共发现了 927 个 DEGs(461 个上调基因和 466 个下调基因)。GO和REACTOME结果显示,DEGs主要富集于蛋白质代谢过程、定位的建立、蛋白质的代谢和新陈代谢。其中,APP、MYH9、TCTN2、USP7、SYNPO、GRB2、HSP90AB1、UBC、HSPA5和SQSTM1被筛选为关键基因。ROC分析提供了枢纽基因的预后价值:结论:潜在的关键基因,尤其是 APP、MYH9、TCTN2、USP7、SYNPO、GRB2、HSP90AB1、UBC、HSPA5 和 SQSTM1,可能与 T2DM 风险有关。我们的研究为 T2DM 的遗传学、分子发病机制和新的治疗靶点提供了新的见解。
{"title":"Bioinformatics Analysis of Next Generation Sequencing Data Identifies Molecular Biomarkers Associated With Type 2 Diabetes Mellitus.","authors":"Varun Alur, Varshita Raju, Basavaraj Vastrad, Chanabasayya Vastrad, Satish Kavatagimath, Shivakumar Kotturshetti","doi":"10.1177/11795514231155635","DOIUrl":"10.1177/11795514231155635","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) is the most common metabolic disorder. The aim of the present investigation was to identify gene signature specific to T2DM.</p><p><strong>Methods: </strong>The next generation sequencing (NGS) dataset GSE81608 was retrieved from the gene expression omnibus (GEO) database and analyzed to identify the differentially expressed genes (DEGs) between T2DM and normal controls. Then, Gene Ontology (GO) and pathway enrichment analysis, protein-protein interaction (PPI) network, modules, miRNA (micro RNA)-hub gene regulatory network construction and TF (transcription factor)-hub gene regulatory network construction, and topological analysis were performed. Receiver operating characteristic curve (ROC) analysis was also performed to verify the prognostic value of hub genes.</p><p><strong>Results: </strong>A total of 927 DEGs (461 were up regulated and 466 down regulated genes) were identified in T2DM. GO and REACTOME results showed that DEGs mainly enriched in protein metabolic process, establishment of localization, metabolism of proteins, and metabolism. The top centrality hub genes <i>APP, MYH9, TCTN2, USP7, SYNPO, GRB2, HSP90AB1, UBC, HSPA5</i>, and <i>SQSTM1</i> were screened out as the critical genes. ROC analysis provides prognostic value of hub genes.</p><p><strong>Conclusion: </strong>The potential crucial genes, especially <i>APP, MYH9, TCTN2, USP7, SYNPO, GRB2, HSP90AB1, UBC, HSPA5</i>, and <i>SQSTM1</i>, might be linked with risk of T2DM. Our study provided novel insights of T2DM into genetics, molecular pathogenesis, and novel therapeutic targets.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"16 ","pages":"11795514231155635"},"PeriodicalIF":2.7,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/78/10.1177_11795514231155635.PMC9944228.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10781818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Characteristics and Outcomes of Diabetic Ketoacidosis in Patients With Type 2 Diabetes using SGLT2 Inhibitors. 使用 SGLT2 抑制剂的 2 型糖尿病患者糖尿病酮症酸中毒的临床特征和预后。
IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-02-10 eCollection Date: 2023-01-01 DOI: 10.1177/11795514231153717
Raya Almazrouei, Bachar Afandi, Fatima AlKindi, Romona Govender, Saif Al-Shamsi

Background: Sodium glucose cotransporter 2 inhibitors (SGLT2i) use is associated with an increased risk of diabetic ketoacidosis (DKA).

Objective: This study evaluated and compared the DKA characteristics and outcomes of users and non-users of SGLT2i.

Methods: We retrospectively studied patients with type 2 diabetes mellitus (T2DM) admitted with DKA to Tawam Hospital, Al Ain City, UAE between January 2017 and March 2021. Demographic data, clinical, and laboratory findings were extracted from the electronic medical records.

Results: A total of 55 patients with T2DM (62% UAE nationals, 50% women) were admitted with DKA. The average age was 54.0 ± 18.9 years and average diabetes duration of 15.7 ± 15.1 years. Seventeen patients (31%) were using SGLT2i. Infection was the main precipitating factor for DKA in (8 out of 17) SGLT2i users. Compared to non-users, SGLT2i users had lower systolic blood pressure (119.9 vs 140 mmHg; P = .012) and serum glucose levels (16.2 vs 24.9 mmol/L; P < .001) and higher Na level (137.5 vs 132.6 mmol/L; P = .005). Additionally, 56.3% of SGLT2i users had euglycemic DKA compared to 2.6% of nonusers (P < .001). Acute kidney injury (AKI) occurred more in SGLT2i users compared to non-users (94.1% vs 67.6%, P = .043). Further analysis revealed that SGLT2i users were about five times more likely to have prolonged hospital length of stay (⩾14 days) when compared with non-users (adjusted OR: 4.84; P = .035). Overall, there was no difference between the two groups with regards to DKA complications and mortality.

Conclusions: SGLT2i related DKA is associated with lower blood glucose levels, lower SBP, worse hypovolemia, increased risk of AKI, and longer hospital stay when compared to non SGLT2i related episodes. Since the benefits of SGLT2 inhibitors far outweigh potential risks, there is a need to raise healthcare professionals and patients' awareness about this potential association.

背景:使用钠葡萄糖共转运体 2 抑制剂(SGLT2i)会增加糖尿病酮症酸中毒(DKA)的风险:使用葡萄糖钠共转运体2抑制剂(SGLT2i)与糖尿病酮症酸中毒(DKA)风险增加有关:本研究评估并比较了SGLT2i使用者和非使用者的DKA特征和结果:我们对 2017 年 1 月至 2021 年 3 月期间阿联酋艾因市塔瓦姆医院收治的 DKA 2 型糖尿病(T2DM)患者进行了回顾性研究。从电子病历中提取了人口统计学数据、临床和实验室检查结果:共有 55 名 T2DM 患者(62% 为阿联酋国民,50% 为女性)因 DKA 入院。平均年龄为(54.0±18.9)岁,平均糖尿病病程为(15.7±15.1)年。17名患者(31%)使用 SGLT2i。在使用 SGLT2i 的患者中,感染是导致 DKA 的主要诱发因素(17 人中有 8 人)。与不使用 SGLT2i 的患者相比,使用 SGLT2i 的患者收缩压(119.9 vs 140 mmHg; P = .012)和血清葡萄糖水平(16.2 vs 24.9 mmol/L; P P = .005)较低。此外,56.3% 的 SGLT2i 使用者患有优生型 DKA,而非使用者仅为 2.6%(P = .043)。进一步分析表明,与不使用 SGLT2i 的患者相比,使用 SGLT2i 的患者住院时间延长(⩾14 天)的几率大约是不使用 SGLT2i 的患者的五倍(调整 OR:4.84;P = .035)。总体而言,两组患者在 DKA 并发症和死亡率方面没有差异:与非 SGLT2i 相关的 DKA 相比,SGLT2i 相关的 DKA 与较低的血糖水平、较低的 SBP、较差的低血容量、较高的 AKI 风险和较长的住院时间有关。由于 SGLT2 抑制剂的益处远远大于潜在风险,因此有必要提高医护人员和患者对这一潜在关联的认识。
{"title":"Clinical Characteristics and Outcomes of Diabetic Ketoacidosis in Patients With Type 2 Diabetes using SGLT2 Inhibitors.","authors":"Raya Almazrouei, Bachar Afandi, Fatima AlKindi, Romona Govender, Saif Al-Shamsi","doi":"10.1177/11795514231153717","DOIUrl":"10.1177/11795514231153717","url":null,"abstract":"<p><strong>Background: </strong>Sodium glucose cotransporter 2 inhibitors (SGLT2i) use is associated with an increased risk of diabetic ketoacidosis (DKA).</p><p><strong>Objective: </strong>This study evaluated and compared the DKA characteristics and outcomes of users and non-users of SGLT2i.</p><p><strong>Methods: </strong>We retrospectively studied patients with type 2 diabetes mellitus (T2DM) admitted with DKA to Tawam Hospital, Al Ain City, UAE between January 2017 and March 2021. Demographic data, clinical, and laboratory findings were extracted from the electronic medical records.</p><p><strong>Results: </strong>A total of 55 patients with T2DM (62% UAE nationals, 50% women) were admitted with DKA. The average age was 54.0 ± 18.9 years and average diabetes duration of 15.7 ± 15.1 years. Seventeen patients (31%) were using SGLT2i. Infection was the main precipitating factor for DKA in (8 out of 17) SGLT2i users. Compared to non-users, SGLT2i users had lower systolic blood pressure (119.9 vs 140 mmHg; <i>P</i> = .012) and serum glucose levels (16.2 vs 24.9 mmol/L; <i>P</i> < .001) and higher Na level (137.5 vs 132.6 mmol/L; <i>P</i> = .005). Additionally, 56.3% of SGLT2i users had euglycemic DKA compared to 2.6% of nonusers (<i>P</i> < .001). Acute kidney injury (AKI) occurred more in SGLT2i users compared to non-users (94.1% vs 67.6%, <i>P</i> = .043). Further analysis revealed that SGLT2i users were about five times more likely to have prolonged hospital length of stay (⩾14 days) when compared with non-users (adjusted OR: 4.84; <i>P</i> = .035). Overall, there was no difference between the two groups with regards to DKA complications and mortality.</p><p><strong>Conclusions: </strong>SGLT2i related DKA is associated with lower blood glucose levels, lower SBP, worse hypovolemia, increased risk of AKI, and longer hospital stay when compared to non SGLT2i related episodes. Since the benefits of SGLT2 inhibitors far outweigh potential risks, there is a need to raise healthcare professionals and patients' awareness about this potential association.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"16 ","pages":"11795514231153717"},"PeriodicalIF":2.7,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/45/b7/10.1177_11795514231153717.PMC9943955.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10789707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stress Induced Cortisol Release Depresses The Secretion of Testosterone in Patients With Type 2 Diabetes Mellitus. 压力诱导的皮质醇释放会抑制 2 型糖尿病患者睾酮的分泌
IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-01-03 eCollection Date: 2023-01-01 DOI: 10.1177/11795514221145841
Safir Ullah Khan, Saba Jannat, Hadia Shaukat, Shiza Unab, Tanzeela, Maleeha Akram, Muhammad Nasir Khan Khattak, Monica Vizcara Soto, Muhammad Fiaz Khan, Amir Ali, Syed Shakeel Raza Rizvi

Background: Both hormonal and genetic data reveal that the stress hormone cortisol and its regulating genes may affect the level of testosterone in humans. It is uncertain whether type 2 diabetes mellitus would manifest similarly. Furthermore, a genetic strategy to screen out the stress system genes that may contribute to testosterone decline in humans is less understood.

Objectives: In this study, we aimed to elucidate the link between stress and testosterone levels, both hormonally and genetically.

Method: This study comprised 37 individuals with type 2 diabetes mellitus and 50 healthy individuals. For the analysis of hormones and the targeted genes, we used the RIA system and bioinformatics expertise.

Results: The patients had significantly elevated cortisol and lower testosterone readings, according to data from hormonal analyses. The bioinformatics approach reveals that SHBG was intracellularly suppressed by 2 defined stress system genes: FKB5 and CYP17. TCF4/TCF8, ATRX, and AR in skeletal muscle were inversely related to stress system genes. Furthermore, all testosterone regulated genes were positively linked with SHBG in the current study. A strong relationship between GNAS and PKA with CYP17 and FKBP5 reveals that the Gαs-cAMP/PKA signaling pathway may be one of the regulatory pathways through which the suppression of testosterone system genes happens. In conclusion, this study demonstrated that beyond stress, the key stress system genes might affect cortisol levels, which in turn affect testosterone figures via the Gαs-cAMP/PKA signaling pathway.

背景:荷尔蒙和遗传学数据显示,压力荷尔蒙皮质醇及其调节基因可能会影响人体睾酮的水平。目前还不确定 2 型糖尿病是否会有类似的表现。此外,筛选出可能导致人类睾酮下降的应激系统基因的遗传策略还不太清楚:在这项研究中,我们旨在从激素和基因两方面阐明压力与睾酮水平之间的联系:方法:这项研究包括 37 名 2 型糖尿病患者和 50 名健康人。在分析激素和目标基因时,我们使用了 RIA 系统和生物信息学专业知识:结果:根据激素分析的数据,患者的皮质醇明显升高,睾酮读数降低。生物信息学方法显示,SHBG 在细胞内受到 2 个确定的应激系统基因的抑制:FKB5和CYP17。骨骼肌中的 TCF4/TCF8、ATRX 和 AR 与应激系统基因成反比。此外,在本研究中,所有睾酮调控基因都与 SHBG 呈正相关。GNAS和PKA与CYP17和FKBP5之间的密切关系表明,Gαs-cAMP/PKA信号通路可能是抑制睾酮系统基因的调控途径之一。总之,这项研究表明,在应激之外,关键的应激系统基因可能会影响皮质醇水平,而皮质醇水平又会通过Gαs-cAMP/PKA信号通路影响睾酮含量。
{"title":"Stress Induced Cortisol Release Depresses The Secretion of Testosterone in Patients With Type 2 Diabetes Mellitus.","authors":"Safir Ullah Khan, Saba Jannat, Hadia Shaukat, Shiza Unab, Tanzeela, Maleeha Akram, Muhammad Nasir Khan Khattak, Monica Vizcara Soto, Muhammad Fiaz Khan, Amir Ali, Syed Shakeel Raza Rizvi","doi":"10.1177/11795514221145841","DOIUrl":"10.1177/11795514221145841","url":null,"abstract":"<p><strong>Background: </strong>Both hormonal and genetic data reveal that the stress hormone cortisol and its regulating genes may affect the level of testosterone in humans. It is uncertain whether type 2 diabetes mellitus would manifest similarly. Furthermore, a genetic strategy to screen out the stress system genes that may contribute to testosterone decline in humans is less understood.</p><p><strong>Objectives: </strong>In this study, we aimed to elucidate the link between stress and testosterone levels, both hormonally and genetically.</p><p><strong>Method: </strong>This study comprised 37 individuals with type 2 diabetes mellitus and 50 healthy individuals. For the analysis of hormones and the targeted genes, we used the RIA system and bioinformatics expertise.</p><p><strong>Results: </strong>The patients had significantly elevated cortisol and lower testosterone readings, according to data from hormonal analyses. The bioinformatics approach reveals that SHBG was intracellularly suppressed by 2 defined stress system genes: FKB5 and CYP17. TCF4/TCF8, ATRX, and AR in skeletal muscle were inversely related to stress system genes. Furthermore, all testosterone regulated genes were positively linked with SHBG in the current study. A strong relationship between GNAS and PKA with CYP17 and FKBP5 reveals that the Gαs-cAMP/PKA signaling pathway may be one of the regulatory pathways through which the suppression of testosterone system genes happens. In conclusion, this study demonstrated that beyond stress, the key stress system genes might affect cortisol levels, which in turn affect testosterone figures via the Gαs-cAMP/PKA signaling pathway.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"16 ","pages":"11795514221145841"},"PeriodicalIF":2.7,"publicationDate":"2023-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8c/6d/10.1177_11795514221145841.PMC9830570.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10528293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipoid Congenital Adrenal Hyperplasia With a Novel StAR Gene Mutation. 脂质先天性肾上腺增生伴一种新的StAR基因突变。
IF 2.8 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-01-01 DOI: 10.1177/11795514231167059
Ayman A Bakkar, Abdulaziz Alsaedi, Naglaa M Kamal, Enad Althobaiti, Lujain A Aboulkhair, Abdullah M Almalki, Shaima A Alsalmi, Qaydah Alharthi, Sara A Abosabie, Salma As Abosabie

Lipoid congenital adrenal hyperplasia (LCAH) is characterized by disturbance of adrenal and gonadal steroidogenesis (OMIM:201710). It is caused by mutation in the Steroidogenic Acute Regulatory Protein (StAR). We report a classic case of LCAH in a neonate (46, XY) with phenotypic female genitalia who presented with significant salt loss with a novel homozygous variant mutation c.745-1G>C p. in StAR gene.

脂质先天性肾上腺增生(LCAH)以肾上腺和性腺甾体生成障碍为特征(OMIM:201710)。它是由类固醇急性调节蛋白(StAR)突变引起的。我们报告了一例典型的LCAH病例,该病例发生在一名新生儿(46,XY),其表型为女性生殖器,在StAR基因中出现了一种新的纯合变异突变C .745- 1g >C . p.,表现为显著的盐损失。
{"title":"Lipoid Congenital Adrenal Hyperplasia With a Novel StAR Gene Mutation.","authors":"Ayman A Bakkar,&nbsp;Abdulaziz Alsaedi,&nbsp;Naglaa M Kamal,&nbsp;Enad Althobaiti,&nbsp;Lujain A Aboulkhair,&nbsp;Abdullah M Almalki,&nbsp;Shaima A Alsalmi,&nbsp;Qaydah Alharthi,&nbsp;Sara A Abosabie,&nbsp;Salma As Abosabie","doi":"10.1177/11795514231167059","DOIUrl":"https://doi.org/10.1177/11795514231167059","url":null,"abstract":"<p><p>Lipoid congenital adrenal hyperplasia (LCAH) is characterized by disturbance of adrenal and gonadal steroidogenesis (OMIM:201710). It is caused by mutation in the Steroidogenic Acute Regulatory Protein (StAR). We report a classic case of LCAH in a neonate (46, XY) with phenotypic female genitalia who presented with significant salt loss with a novel homozygous variant mutation c.745-1G>C p. in StAR gene.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"16 ","pages":"11795514231167059"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/0d/10.1177_11795514231167059.PMC10226314.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9553264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Degraded Bone Microarchitecture in Women with PHPT-Significant Predictor of Fracture Probability. phpt患者骨微结构退化——骨折概率的重要预测因子。
IF 2.8 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-01-01 DOI: 10.1177/11795514221145840
Theodor Eugen Oprea, Carmen Gabriela Barbu, Sorina Carmen Martin, Anca Elena Sarbu, Simona Gabriela Duta, Irina Manuela Nistor, Simona Fica

Introduction: Patients with primary hyperparathyroidism (PHPT) experience bone mineral density (BMD) loss and trabecular bone score (TBS) alteration, which current guidelines recommend assessing. Considering TBS alongside BMD for a 10-year fracture risk assessment (FRAX) may improve PHPT management.

Design: Retrospective, cross-sectional study composed of 49 Caucasian females (62 ± 10.6 years, 27.7 ± 0.87 kg/m2) with PHPT and 132 matched control subjects (61.3 ± 10.5 years, 27.5 ± 0.49 kg/m2) evaluated in 3 years. We assessed lumbar spine (LS) and femoral neck (FN) BMD, T and Z scores (GE Healthcare Lunar Osteodensitometer) and TBS (iNsight 1.8), major osteoporotic fracture (MOF), and hip FRAX.

Results: Patients with PHPT had statistically lower mean values for lumbar spine bone mineral density (LS BMD) (0.95 ± 0.25 vs 1.01 ± 0.14 g/cm2, P = .01), LS T-scores (-2 ± 0.2 vs -1.4 ± 0.1 SD, P = .009), LS Z scores (-0.9 ± 0.19 vs -0.1 ± 0.11 SD, P = .009), femoral neck bone mineral density (FN BMD) (0.79 ± 0.02 vs 0.83 ± 0.01 g/cm2, P = .02), FN T-scores (-1.8 ± 0.13 vs -1.5 ± 0.07 SD, P = .017), FN Z scores (-0.51 ± 0.87 vs -0.1 ± 0.82 SD, P = .006), and TBS (0.95 ± 0.25 vs 1.01 ± 0.14 g/cm2, P = .01) compared with control subjects. 22.4% of patients with PHPT had degraded microarchitecture (TBS < 1.2) vs. 7.6% in control group (χ2 = 0.008). PHPT proved to be a covariate with unique contribution (P = .031) alongside LS BMD (P = .040) in a linear regression model [R 2 = 0.532, F(4,16) = 4.543] for TBS < 1.2. TBS adjustment elevated MOF FRAX both for PHPT (4.35  ± 0.6% vs 5.25% ± 0.73%, P < .001) and control groups (4.5  ± 0.24% vs 4.7% ± 0.26%, P < .001) compared with BMD-bases FRAX, but also increased differently between the 2 study groups (1.1-folds for PHPT patients and 1.04 for control subjects, P = .034).

Conclusion: Compared with control, TBS-adjusted FRAX provides significantly higher MOF risk than BMD-based FRAX in PHPT women.

原发性甲状旁腺功能亢进(PHPT)患者会经历骨密度(BMD)丢失和骨小梁评分(TBS)改变,目前的指南建议对其进行评估。考虑TBS和BMD一起进行10年骨折风险评估(FRAX)可能会改善PHPT的管理。设计:回顾性横断面研究,由49名患有PHPT的高加索女性(62±10.6岁,27.7±0.87 kg/m2)和132名匹配的对照组(61.3±10.5岁,27.5±0.49 kg/m2)组成,3年内评估。我们评估了腰椎(LS)和股骨颈(FN) BMD、T和Z评分(GE Healthcare月相骨密度计)和TBS (iNsight 1.8)、主要骨质疏松性骨折(MOF)和髋部FRAX。结果:PHPT患者统计平均值低了腰椎骨矿物质密度(LS BMD)(0.95±0.25 vs 1.01±0.14克/厘米2,P = . 01), LS t指数(2±0.2 vs -1.4±0.1 SD, P = .009), LS Z得分(-0.9±0.19 vs -0.1±0.11 SD, P = .009),股骨颈骨密度(FN BMD)(0.79±0.02 vs 0.83±0.01克/厘米2,P = .02点),FN t指数(-1.8±0.13 vs -1.5±0.07 SD, P = .017), FN Z得分(-0.51±0.87 vs -0.1±0.82 SD, P = .006),和TBS(0.95±0.25 vs 1.01±0.14克/厘米2,P = 0.01)。22.4%的PHPT患者微结构退化(TBS 2 = 0.008)。在线性回归模型(r2 = 0.532, F(4,16) = 4.543)中,PHPT与LS BMD (P = 0.040)一起被证明是具有独特贡献的协变量(P = 0.031)。结论:与对照组相比,经tbs调整的FRAX在PHPT女性中提供的MOF风险明显高于基于bmd的FRAX。
{"title":"Degraded Bone Microarchitecture in Women with PHPT-Significant Predictor of Fracture Probability.","authors":"Theodor Eugen Oprea,&nbsp;Carmen Gabriela Barbu,&nbsp;Sorina Carmen Martin,&nbsp;Anca Elena Sarbu,&nbsp;Simona Gabriela Duta,&nbsp;Irina Manuela Nistor,&nbsp;Simona Fica","doi":"10.1177/11795514221145840","DOIUrl":"https://doi.org/10.1177/11795514221145840","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with primary hyperparathyroidism (PHPT) experience bone mineral density (BMD) loss and trabecular bone score (TBS) alteration, which current guidelines recommend assessing. Considering TBS alongside BMD for a 10-year fracture risk assessment (FRAX) may improve PHPT management.</p><p><strong>Design: </strong>Retrospective, cross-sectional study composed of 49 Caucasian females (62 ± 10.6 years, 27.7 ± 0.87 kg/m<sup>2</sup>) with PHPT and 132 matched control subjects (61.3 ± 10.5 years, 27.5 ± 0.49 kg/m<sup>2</sup>) evaluated in 3 years. We assessed lumbar spine (LS) and femoral neck (FN) BMD, T and Z scores (GE Healthcare Lunar Osteodensitometer) and TBS (iNsight 1.8), major osteoporotic fracture (MOF), and hip FRAX.</p><p><strong>Results: </strong>Patients with PHPT had statistically lower mean values for lumbar spine bone mineral density (LS BMD) (0.95 ± 0.25 vs 1.01 ± 0.14 g/cm<sup>2</sup>, <i>P</i> = .01), LS T-scores (-2 ± 0.2 vs -1.4 ± 0.1 SD, <i>P</i> = .009), LS Z scores (-0.9 ± 0.19 vs -0.1 ± 0.11 SD, <i>P</i> = .009), femoral neck bone mineral density (FN BMD) (0.79 ± 0.02 vs 0.83 ± 0.01 g/cm<sup>2</sup>, <i>P</i> = .02), FN T-scores (-1.8 ± 0.13 vs -1.5 ± 0.07 SD, <i>P</i> = .017), FN Z scores (-0.51 ± 0.87 vs -0.1 ± 0.82 SD, <i>P</i> = .006), and TBS (0.95 ± 0.25 vs 1.01 ± 0.14 g/cm<sup>2</sup>, <i>P</i> = .01) compared with control subjects. 22.4% of patients with PHPT had degraded microarchitecture (TBS < 1.2) vs. 7.6% in control group (χ<sup>2</sup> = 0.008). PHPT proved to be a covariate with unique contribution (<i>P</i> = .031) alongside LS BMD (<i>P</i> = .040) in a linear regression model [<i>R</i> <sup>2</sup> = 0.532, <i>F(4,16)</i> = 4.543] for TBS < 1.2. TBS adjustment elevated MOF FRAX both for PHPT (4.35  ± 0.6% vs 5.25% ± 0.73%, <i>P</i> < .001) and control groups (4.5  ± 0.24% vs 4.7% ± 0.26%, <i>P</i> < .001) compared with BMD-bases FRAX, but also increased differently between the 2 study groups (1.1-folds for PHPT patients and 1.04 for control subjects, <i>P</i> = .034).</p><p><strong>Conclusion: </strong>Compared with control, TBS-adjusted FRAX provides significantly higher MOF risk than BMD-based FRAX in PHPT women.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"16 ","pages":"11795514221145840"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/10/10.1177_11795514221145840.PMC9869236.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10627756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Cortisol-Secreting Adrenal Adenoma Combined With a Micro-Pheochromocytoma: Case Report and Literature Review. 肾上腺皮质分泌腺瘤合并微嗜铬细胞瘤1例并文献复习。
IF 2.8 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-01-01 DOI: 10.1177/11795514221148556
Kimiko Sakai, Mai Asano, Masahide Hamaguchi, Hidefumi Taniguchi, Osamu Ukimura, Michiaki Fukui

Cushing's syndrome and pheochromocytomas (PCCs) are associated with endocrine hypertension. Cortisol-producing adrenal adenomas are a major cause of Cushing's syndrome. Simultaneous occurrence of cortisol-producing adrenal adenomas and PCCs is rare. Additionally, a PCC generally produces catecholamines in proportion to its size; therefore, micro-PCCs are rarely found in clinical practice. It is unknown whether micro-PCCs produce excess catecholamines during the pre-biochemical phase. Herein, we report the case of a 53-year-old woman who was referred to our hospital for further evaluation of left adrenal incidentaloma. She had been suffering from hypertension for 7 years. Endocrine tests indicated autonomous cortisol secretion, and she was diagnosed with cortisol-producing adrenal adenoma. A laparoscopic left adrenalectomy was performed. The final pathological examination revealed an adrenocortical adenoma measuring 26 × 24 mm. In addition, a micro-PCC measuring 3 × 2 mm was incidentally found near the cortisol-secreting adrenal adenoma in the ipsilateral adrenal gland. All catecholamine biosynthetic enzymes, tyrosine hydroxylase, aromatic l-amino acid decarboxylase, dopamine β-hydroxylase, and phenyl ethanolamine N-methyltransferase, were detected in this micro-PCC by immunohistochemical analyses. Although catecholamine levels were not biochemically elevated, the PCC expressed catecholamine biosynthetic enzymes. This is the first immunohistochemical report to show that a micro-PCC produces excess catecholamines in the pre-biochemical phase.

库欣综合征和嗜铬细胞瘤(PCCs)与内分泌高血压有关。产生皮质醇的肾上腺腺瘤是导致库欣综合征的主要原因。同时发生促肾上腺皮质激素腺瘤和PCCs是罕见的。此外,PCC产生的儿茶酚胺通常与其大小成比例;因此,临床上很少发现微型pccs。目前尚不清楚微pccs是否在生化前阶段产生过量的儿茶酚胺。在此,我们报告一位53岁的女性,她被转介到我们医院进一步评估左肾上腺偶发瘤。她患高血压已经7年了。内分泌测试显示自主皮质醇分泌,她被诊断为肾上腺分泌皮质醇腺瘤。行腹腔镜左肾上腺切除术。最终病理检查示肾上腺皮质腺瘤,大小为26 × 24 mm。此外,在同侧肾上腺分泌肾上腺腺瘤附近偶然发现一个3 × 2mm的微型pcc。免疫组化检测了所有儿茶酚胺生物合成酶、酪氨酸羟化酶、芳香l-氨基酸脱羧酶、多巴胺β-羟化酶和苯基乙醇胺n -甲基转移酶。虽然儿茶酚胺水平没有生化升高,但PCC表达了儿茶酚胺生物合成酶。这是第一个免疫组织化学报告显示,微pcc在生化前阶段产生过量的儿茶酚胺。
{"title":"A Cortisol-Secreting Adrenal Adenoma Combined With a Micro-Pheochromocytoma: Case Report and Literature Review.","authors":"Kimiko Sakai,&nbsp;Mai Asano,&nbsp;Masahide Hamaguchi,&nbsp;Hidefumi Taniguchi,&nbsp;Osamu Ukimura,&nbsp;Michiaki Fukui","doi":"10.1177/11795514221148556","DOIUrl":"https://doi.org/10.1177/11795514221148556","url":null,"abstract":"<p><p>Cushing's syndrome and pheochromocytomas (PCCs) are associated with endocrine hypertension. Cortisol-producing adrenal adenomas are a major cause of Cushing's syndrome. Simultaneous occurrence of cortisol-producing adrenal adenomas and PCCs is rare. Additionally, a PCC generally produces catecholamines in proportion to its size; therefore, micro-PCCs are rarely found in clinical practice. It is unknown whether micro-PCCs produce excess catecholamines during the pre-biochemical phase. Herein, we report the case of a 53-year-old woman who was referred to our hospital for further evaluation of left adrenal incidentaloma. She had been suffering from hypertension for 7 years. Endocrine tests indicated autonomous cortisol secretion, and she was diagnosed with cortisol-producing adrenal adenoma. A laparoscopic left adrenalectomy was performed. The final pathological examination revealed an adrenocortical adenoma measuring 26 × 24 mm. In addition, a micro-PCC measuring 3 × 2 mm was incidentally found near the cortisol-secreting adrenal adenoma in the ipsilateral adrenal gland. All catecholamine biosynthetic enzymes, tyrosine hydroxylase, aromatic l-amino acid decarboxylase, dopamine β-hydroxylase, and phenyl ethanolamine N-methyltransferase, were detected in this micro-PCC by immunohistochemical analyses. Although catecholamine levels were not biochemically elevated, the PCC expressed catecholamine biosynthetic enzymes. This is the first immunohistochemical report to show that a micro-PCC produces excess catecholamines in the pre-biochemical phase.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"16 ","pages":"11795514221148556"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/a4/10.1177_11795514221148556.PMC9846587.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10582083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Influence of COVID-19 in Endocrine Research: Critical Overview, Methodological Implications and a Guideline for Future Designs. COVID-19对内分泌研究的影响:关键综述、方法学意义和未来设计指南。
IF 2.8 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-01-01 DOI: 10.1177/11795514231189073
Reza Rastmanesh, Lucky Krishnia, Manoj Kumar Kashyap

The COVID-19 pandemic has changed many aspects of people's lives, including not only individual social behavior, healthcare procedures, and altered physiological and pathophysiological responses. As a result, some medical studies may be influenced by one or more hidden factors brought about by the COVID-19 pandemic. Using the literature review method, we are briefly discussing the studies that are confounded by COVID-19 and facemask-induced partiality and how these factors can be further complicated with other confounding variables. Facemask wearing has been reported to produce partiality in studies of ophthalmology (particularly dry eye and related ocular diseases), sleep studies, cognitive studies (such as emotion-recognition accuracy research, etc.), and gender-influenced studies, to mention a few. There is a possibility that some other COVID-19 related influences remain unrecognized in medical research. To account for heterogeneity, current and future studies need to consider the severity of the initial illness (such as diabetes, other endocrine disorders), and COVID-19 infection, the timing of analysis, or the presence of a control group. Face mask-induced influences may confound the results of diabetes studies in many ways.

2019冠状病毒病大流行改变了人们生活的许多方面,不仅包括个人社会行为、医疗保健程序以及改变的生理和病理生理反应。因此,一些医学研究可能会受到新冠肺炎大流行带来的一个或多个隐藏因素的影响。采用文献回顾法,我们简要讨论了COVID-19和口罩引起的偏见混淆的研究,以及这些因素如何与其他混淆变量进一步复杂化。据报道,在眼科研究(特别是干眼症和相关眼部疾病)、睡眠研究、认知研究(如情绪识别准确性研究等)和性别影响研究中,戴口罩会产生偏见。有可能在医学研究中仍未认识到其他与COVID-19相关的影响。为了解释异质性,当前和未来的研究需要考虑初始疾病(如糖尿病、其他内分泌紊乱)的严重程度、COVID-19感染、分析时间或对照组的存在。口罩引起的影响可能会在许多方面混淆糖尿病研究的结果。
{"title":"The Influence of COVID-19 in Endocrine Research: Critical Overview, Methodological Implications and a Guideline for Future Designs.","authors":"Reza Rastmanesh,&nbsp;Lucky Krishnia,&nbsp;Manoj Kumar Kashyap","doi":"10.1177/11795514231189073","DOIUrl":"https://doi.org/10.1177/11795514231189073","url":null,"abstract":"<p><p>The COVID-19 pandemic has changed many aspects of people's lives, including not only individual social behavior, healthcare procedures, and altered physiological and pathophysiological responses. As a result, some medical studies may be influenced by one or more hidden factors brought about by the COVID-19 pandemic. Using the literature review method, we are briefly discussing the studies that are confounded by COVID-19 and facemask-induced partiality and how these factors can be further complicated with other confounding variables. Facemask wearing has been reported to produce partiality in studies of ophthalmology (particularly dry eye and related ocular diseases), sleep studies, cognitive studies (such as emotion-recognition accuracy research, etc.), and gender-influenced studies, to mention a few. There is a possibility that some other COVID-19 related influences remain unrecognized in medical research. To account for heterogeneity, current and future studies need to consider the severity of the initial illness (such as diabetes, other endocrine disorders), and COVID-19 infection, the timing of analysis, or the presence of a control group. Face mask-induced influences may confound the results of diabetes studies in many ways.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"16 ","pages":"11795514231189073"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b0/4b/10.1177_11795514231189073.PMC10387761.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10649803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Medicine Insights-Endocrinology and Diabetes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1